Cargando…

Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms

Detalles Bibliográficos
Autores principales:	Shih, Lauren, Othus, Megan, Schonhoff, Kelda, Shaw, Carole, Appelbaum, Jacob, Halpern, Anna B., Becker, Pamela S., Walter, Roland B., Estey, Elihu, Percival, Mary-Elizabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457180/ https://www.ncbi.nlm.nih.gov/pubmed/37524920 http://dx.doi.org/10.1038/s41375-023-01981-2

Ejemplares similares

Effect of ECOG performance status on outcomes in patients with acute myeloid leukemia and other high-grade myeloid neoplasms
por: Paras, Gabrielle, et al.
Publicado: (2022)

Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility
por: Percival, Mary-Elizabeth M., et al.
Publicado: (2020)

Effect of Measurable (“Minimal”) Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia
por: Othus, Megan, et al.
Publicado: (2016)

Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms: A Phase 1/2 Study
por: Halpern, Anna B., et al.
Publicado: (2017)

Phase 1/2 Trial of GCLAM with Dose-Escalated Mitoxantrone for Newly Diagnosed AML or Other High-Grade Myeloid Neoplasms
por: Halpern, Anna B., et al.
Publicado: (2018)

Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
por: Godwin, Colin D., et al.
Publicado: (2022)

Pre- and Post-Transplant Quantification of Measurable (“Minimal”) Residual Disease via Multiparameter Flow Cytometry in Adult Acute Myeloid Leukemia
por: Zhou, Yi, et al.
Publicado: (2016)

Improved outcomes with “7+3” induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data
por: Othus, Megan, et al.
Publicado: (2022)

Invasive fungal infections after CLAG-M/CLAG chemotherapy for acute myeloid leukemia and high-grade myeloid neoplasms
por: Lindsay, Julian, et al.
Publicado: (2023)

Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation
por: Rodríguez-Arbolí, Eduardo, et al.
Publicado: (2022)

New drug approvals in acute myeloid leukemia: what’s the best end point?
por: Estey, E, et al.
Publicado: (2015)

Regimen‐intensity per count‐recovery and hospitalization index: A new tool to assign regimen intensity for AML
por: Sorror, Mohamed L., et al.
Publicado: (2020)

Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification
por: Hochman, Michael J., et al.
Publicado: (2023)

Relative survival following response to 7+3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes:An analysis of four SWOG studies
por: Othus, Megan, et al.
Publicado: (2018)

Prediction of CR following a second course of ‘7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course
por: Othus, M, et al.
Publicado: (2016)

Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML)
por: Acharya, Utkarsh H., et al.
Publicado: (2018)

Effect of Genetic Profiling on Prediction of Therapeutic Resistance and Survival in Adult Acute Myeloid Leukemia
por: Walter, Roland B., et al.
Publicado: (2015)

Acute myeloid leukaemia relapse presenting as cardiac myeloid sarcoma
por: Waselewski, Alexander, et al.
Publicado: (2018)

Treatment of Relapsed Acute Myeloid Leukemia
por: Thol, Felicitas, et al.
Publicado: (2020)

Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia
por: Orvain, Corentin, et al.
Publicado: (2022)

Isolated Intracranial Myeloid Sarcoma Occurring as Relapse in Acute Myeloid Leukemia
por: Narayanan, Geetha, et al.
Publicado: (2017)

Treatment for Relapsed/Refractory Acute Myeloid Leukemia
por: Thol, Felicitas, et al.
Publicado: (2021)

Colonic Myeloid Sarcoma as a Rare Presentation of Relapsed Acute Myeloid Leukemia
por: Phatharacharukul, Parkpoom, et al.
Publicado: (2020)

Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component
por: Platte, Victoria, et al.
Publicado: (2022)

Measurable Residual Disease-Guided Treatment to Prevent Relapse in Acute Myeloid Leukemia and Myelodysplastic Syndrome
por: Pan, Jonathan, et al.
Publicado: (2020)

Acute myeloid leukemia maturation lineage influences residual disease and relapse following differentiation therapy
por: Ngo, Steven, et al.
Publicado: (2021)

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
por: Goswami, Meghali, et al.
Publicado: (2022)

Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML
por: Halpern, Anna B., et al.
Publicado: (2023)

Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia
por: Rapaport, Franck, et al.
Publicado: (2021)

Relapsed acute myeloid leukemia presenting as conjunctival myeloid sarcoma: a case report
por: Park, Joong Hyun, et al.
Publicado: (2022)

Relapsing acute myeloid leukemia presenting as hypopyon uveitis
por: Hegde, Sapna P, et al.
Publicado: (2011)

Isolated CNS leukaemic relapse in acute myeloid leukaemia
por: Essa, Amr, et al.
Publicado: (2019)

Paraplegia as a Rare Clinical Presentation of Relapsed Acute Myeloid Leukemia
por: Osman, Haitham, et al.
Publicado: (2023)

Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia
por: Popescu, Bogdan, et al.
Publicado: (2019)

Development and Validation of a Novel Acute Myeloid Leukemia–Composite Model to Estimate Risks of Mortality
por: Sorror, Mohamed L., et al.
Publicado: (2017)

Isolated Central Nervous System Relapse in Chronic Myeloid Leukemia
por: Gomez, Juliana, et al.
Publicado: (2015)

Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
por: Ramos, Nestor R., et al.
Publicado: (2015)

Clonal evolution of acute myeloid leukemia from diagnosis to relapse
por: Vosberg, Sebastian, et al.
Publicado: (2019)

Isolated leukemia cutis as extramedullary relapse of acute myeloid leukemia
por: Dadrass, Farinoosh, et al.
Publicado: (2022)

Brachytherapy for uterine cervix-limited acute myeloid leukemia relapse
por: Beziat, Guillaume, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s2tcp5u5is4itt6ta1dhbec1lc